Adagene Inc.
ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-huā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.02
Price-1.71%
-$0.07
1Y
Price
Market Cap
$151.347m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-71.3%
EBITDA Margin-53.9%
Net Profit Margin-59.3%
Free Cash Flow Margin-71.3%
EBITDA Margin-53.9%
Net Profit Margin-59.3%
Free Cash Flow MarginRevenue
$7.671m
+7454.4%
1y CAGR+2483.3%
3y CAGR+1860.3%
5y CAGREarnings
-$17.609m
-52.8%
1y CAGR-17.6%
3y CAGR-15.5%
5y CAGREPS
-$0.46
-49.5%
1y CAGR-16.3%
3y CAGR-12.4%
5y CAGRBook Value
$35.350m
$78.263m
Assets$42.914m
Liabilities$6.263m
DebtDebt to Assets
8.0%
-0.1x
Debt to EBITDAFree Cash Flow
-$15.674m
-52.9%
1y CAGR-5.0%
3y CAGR-5.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company